Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

LDP-02 (Millenium).

¹Department of Medicine, McMaster University, Hamilton, Ontario, Canada. marshallj@mcmaster.ca

Current Opinion in Investigational Drugs (London, England : 2000)

|September 22, 2001

Summary

This summary is machine-generated.

LDP-02, a novel antibody targeting alpha4beta7 integrin, is being developed for inflammatory bowel diseases (IBD). Preclinical studies and a phase II grant supported its development for conditions like Crohn's disease and ulcerative colitis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Declining Use of Corticosteroids for Crohn's Disease Has Implications for Study Recruitment: Results of a Pilot Randomized Controlled Trial.

Journal of the Canadian Association of Gastroenterology·2021

Same author

Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease.

Alimentary pharmacology & therapeutics·2013

Same author

Meta-analysis: peri-operative anti-TNFα treatment and post-operative complications in patients with inflammatory bowel disease.

Alimentary pharmacology & therapeutics·2013

Same author

Meta-analysis: colonoscopic post-polypectomy bleeding in patients on continued clopidogrel therapy.

Alimentary pharmacology & therapeutics·2013

Same author

Effect of wheat distillers dried grains with solubles or sugar beet pulp on prevalence of Salmonella enterica Typhimurium in weaned pigs.

Journal of animal science·2013

Same author

Clustering and stability of functional lower gastrointestinal symptom after enteric infection.

Neurogastroenterology and motility·2012

Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011

Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010

See all related articles

Area of Science:

Immunology
Gastroenterology
Pharmacology

Background:

Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, represent significant unmet medical needs.
Leukocyte trafficking via the alpha4beta7 integrin receptor plays a key role in gastrointestinal inflammation.

Purpose of the Study:

To develop and evaluate LDP-02, a humanized monoclonal antibody targeting the alpha4beta7 integrin receptor.
To assess the potential of LDP-02 for the treatment of inflammatory bowel diseases.

Main Methods:

Development of LDP-02, a humanized monoclonal antibody.
Preclinical testing of LDP-02 for inflammatory bowel disease treatment.
Collaboration between Millennium (LeukoSite) and Genentech for development and commercialization.

Related Experiment Videos

Main Results:

LDP-02 targets the alpha4beta7 integrin receptor on leukocytes.
Phase II SBIR grant awarded for LDP-02 development and preclinical testing.
Analysts predicted a 10% probability of market entry with estimated peak sales of $250 million.

Conclusions:

LDP-02 shows potential as a therapeutic agent for inflammatory bowel diseases.
Further development and clinical trials are necessary to confirm efficacy and safety.
The drug's commercial viability is under evaluation, with projected significant market potential.